A minor leakage happened while loading dimethyl sulphate. Later as a precaution, 22
workers were admitted to a local hospital for observation of which more than half of them has
been discharged already.
1 Like
great insight,would appreciate if you can share source,but anyways Great Work
i must clarify these are almost Peak Assumptions & made with chatgpt deep research,Having Said that Currently in Aarti Pharamlabs had around 270 cr Revenue in FY 25 Which is expected to be around 354 cr ( with 30% growth guided by mgmt),Even if we take 50% discount to the assumption made here ,CDMO Segment it self can double from current Annual Sales ,which can be trigger for margin improvement
3 Likes
Reviving this thread with some regulatory data that has not been discussed here, all from the last two weeks.
FDA Form 483 Unit IV, Tarapur - March 27, 2026
US FDA completed an inspection of Unit-IV at Tarapur on March 27, 2026. The company received a Form 483 with one observation, described by the company as procedural in nature. CAPA to be submitted within stipulated timeline.
One observation with a procedural characterisation is broadly positive it suggests the facility is in reasonable shape. The key question is what “procedural” means specifically. FDA does not use that word in the 483 itself — that framing comes from the company. The actual observation text will be available on the FDA website in 20-30 days. Worth checking once it is published to confirm the characterisation is accurate.
Chemical leak Unit VI, Tarapur - March 22, 2026
Five days before the FDA inspection concluded at Unit IV, a different unit had a more significant incident. A dimethyl sulphate leak occurred during tanker loading at Unit VI on March 22, 2026. Twenty-two workers were hospitalised as a precaution. Normal operations resumed within 24 hours. A police FIR has been registered and investigation is underway.
Dimethyl sulphate is classified as a highly toxic chemical it is a Schedule 1 chemical under the Chemical Weapons Convention at high concentrations and causes severe respiratory and skin damage on exposure. This is not a minor chemical.
The Tarapur MIDC area has witnessed multiple industrial accidents in recent weeks a gas leak at Bhageria Industries affecting 2,600 people on March 2, leaks at Vinayak Chemex, and a fire at Shiv Industries MPCB is likely to conduct enhanced inspections across all Tarapur MIDC units given this pattern. Whether Aarti Pharmalabs’ Unit VI gets a formal show cause or inspection notice from MPCB in the coming weeks is worth monitoring.
Delayed SEBI disclosure - February 2026
The company missed the mandatory 24-hour SEBI Regulation 30 disclosure timeline in February 2026 and submitted a clarification to BSE on February 13 explaining that the responsible official was on leave from February 3-5.
A one-off delay explained by leave is understandable. But a company that missed a Regulation 30 deadline in February and then had a chemical leak requiring hospitalisation of 22 workers in March five days before an FDA inspection concluded is dealing with a compressed operational and regulatory calendar that deserves scrutiny.
Promoter pledge - March 25, 2026
Promoter Mirik Rajendra Gogri pledged 27,84,094 shares 3.08% of total share capital on March 25, 2026 with Bajaj Financial Securities and 360 One Distribution Services.
Worth noting: promoter pledging shares five days before an FDA inspection concludes, in the same week as a chemical leak incident. These may be entirely unrelated — pledges often reflect personal financial planning rather than company stress. But the timing is worth flagging for those monitoring closely.
The financial backdrop
Q3 FY26 net profit declined 35.2% and revenue fell 19.6% year on year. A deteriorating financial performance quarter, a chemical leak requiring hospitalisations, a missed disclosure deadline, an active FDA inspection, and a promoter pledge all within the last six weeks.
None of these individually is a red flag. Together they suggest this is a company under more pressure than the thread discussion from 2023 would suggest. Monitoring closely.
Not holding. All data from BSE Regulation 30 filings, FDA public disclosures, and press reports.
12 Likes
Does anyone have access to the export data for Q4 FY26
1 Like